ID 200066221 · FY 2017–2024 · 8 years
Group parent — controls 1 company
Georgian pharmacy/pharmaceutical company under the Demasi brand. Limited public information available beyond the Reportal filing.
curated 2026-06-03reportal.ge
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 53,565 | 60,346 | 56,605 | 54,509 | 72,367 | 87,511 | 87,182 | 90,682 | +7.8% |
| Total COGS | -31,349 | -34,995 | -32,099 | -31,212 | -41,588 | -51,336 | -52,154 | -53,579 | +8.0% |
| Gross Profit | 22,216 | 25,351 | 24,506 | 23,297 | 30,779 | 36,175 | 35,028 | 37,103 | +7.6% |
| Gross Margin | 41.5% | 42.0% | 43.3% | 42.7% | 42.5% | 41.3% | 40.2% | 40.9% | |
| Total Operating Expenses | -1,958 | -7,633 | -7,937 | -8,492 | -9,858 | -10,654 | -12,325 | -17,011 | +36.2% |
| EBITDA | 20,258 | 17,718 | 16,569 | 14,805 | 20,921 | 25,521 | 22,703 | 20,092 | -0.1% |
| EBITDA Margin | 37.8% | 29.4% | 29.3% | 27.2% | 28.9% | 29.2% | 26.0% | 22.2% | |
| Total D&A | -1,035 | -1,103 | -1,352 | -1,552 | -1,901 | -2,014 | -2,008 | -2,697 | +14.7% |
| EBIT / Operating Income | 19,223 | 16,615 | 15,217 | 13,253 | 19,020 | 23,507 | 20,695 | 17,395 | -1.4% |
| Total Interest Income | 1,102 | 2,444 | 2,953 | 3,620 | 2,860 | 619 | 891 | 2,400 | +11.8% |
| Total Interest Expense | 0 | 0 | -75 | -940 | -3,499 | -278 | -18 | -249 | +27.1% |
| Total Other Income | 612 | 2,277 | 3,594 | 9,793 | -206 | -132 | -1,873 | 2,519 | +22.4% |
| Profit Before Tax | 20,937 | 21,336 | 21,689 | 25,726 | 18,175 | 23,716 | 19,695 | 22,065 | +0.8% |
| Total Income Tax | 0 | -211 | -44 | -1,469 | -47 | -3 | -620 | -15 | -35.6% |
| Net Profit / (Loss) | 16,857 | 20,953 | 21,424 | 24,009 | 17,847 | 23,430 | 19,075 | 22,050 | +3.9% |
| Net Margin | 31.5% | 34.7% | 37.8% | 44.0% | 24.7% | 26.8% | 21.9% | 24.3% |
Ownership & directors from companyinfo.ge (public corporate registry).